糖鎖生物学の世界市場：製品タイプ、アプリケーション、エンドユーザー、地理別の成長率、動向および予測

糖鎖生物学は、2018年から2023年の予測期間中に、約13％のCAGRで成長すると見込まれています。糖鎖生物学は、生命科学の重要な分野であり、細菌生理学の研究、新規薬物の開発およびプロテオミクス研究において多様な役割を果たす糖鎖の研究を含んでいます。研究者は、糖鎖応用のために、質量分析、MALDI-TOFなどの様々な技術を活用しています。したがって、質量分析計およびMALDI-TOF質量分析計を含む糖鎖生物学機器の需要は、近い将来に増加すると予想されます。

当レポートでは、世界の糖鎖生物学市場を調査し、全体的な市場動向、製品・地域別の詳細動向、市場成長への影響要因の分析、競合情勢、主要企業のプロファイルなどを包括的にまとめています。

目次

第1章 イントロダクション

• 市場の定義

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 主な推論

第5章 市場の概要

• 現在の市場シナリオ
• ポーターのファイブフォース分析
  • サプライヤーの交渉力
  • 消費者の交渉力
  • 新規参入の脅威
  • 代替製品とサービスの脅威
  • 業界内での競争

第6章 成長要因、阻害要因、機会、課題の分析（DROC）

• 市場の成長要因
  • 糖鎖生物学およびプロテオミクス研究向けの政府および民間資金調達の増加
  • 医薬品およびバイオテクノロジー企業による研究開発費の増加
• 市場の阻害要因
  • 高い製品コスト
  • 熟練した専門家の低可用性
• 市場機会
• 主な課題

第7章 市場セグメンテーション

• 製品別
  • 酵素
  • 器具
  • キット
  • 試薬
• アプリケーション別
  • 診断
  • 創薬開発
  • 腫瘍学
  • 免疫学
  • その他
• エンドユーザー
  • 医薬品およびバイオテクノロジー企業
  • 契約研究機関（CRO）
  • その他
• 地域別
  • 北米
  • 欧州
  • アジア太平洋地域
  • 中東・アフリカ
  • 南米

第8章 競合情勢

• M&A分析
• 合意、コラボレーション、パートナーシップ
• 新製品の発売

第9章 主要企業

• Agilent Technologies
• Bruker Corporation
• Danaher Corporation
• Merck KGaA
• New England Biolabs
• ProZyme
• 島津製作所
• タカラバイオ
• Thermo Fisher Scientific
• Waters Corporation など

第10章 市場の将来展望

The glycobiology market will show rapid growth due to the increasing government and private funding for glycomics and proteomics research and growing R&D expenditure by pharmaceutical and biotechnology companies.

• The major pharmaceutical and biotech companies are heavily investing in the research and development of superior biological products, such as glycobiology products and products related to proteomics.
• There is also an increased demand for curative treatments for many life-threatening diseases, such as cancer, which is expected to drive the pace of pharmaceutical and biotechnological R&D, as well as overall investments made in glycobiology field. This makes glycobiology an attractive option for big pharma and biotech companies to invest in. Furthermore, glycomic biomarkers have significant applications in drug development and diagnostics for many diseases.
• In addition, a huge amount of investment is put into the development of its products and the approval of drugs that are developed, require a lot of regulatory stages that are necessary for the process. This, in turn, renders these products very expensive.

Key Market Trends

Drug Discovery and Development is Expected to be the Largest Growing Segment

On the basis of application, drug discovery and development has been accounted for the largest market share. This is primarily owing to extensive R&D and increased government funding for research related to glycomics and proteomics. There is an increasing R&D investments by pharmaceutical companies, which increases the drug discovery and development of glycomics. For instance, R&D expenditure of Merck accounted for USD 9.8 billion, in 2018.

The other applications segment is anticipated to witness the high CAGR due to rising clinical trials and R&D expenses incurred by key companies for research.

North America is Found Leading the Glycobiology Market

North America has been accounted for the largest market share due to the presence of key pharmaceutical and biopharmaceutical companies. The presence of well-established healthcare infrastructure and accessibility to advanced products have driven the regional market. Moreover, there is also increasing applications of glycans in various cancers and increasing funds from the government in enhancing the field of glycobioogy, that helps the market to grow over the forecast period.

Competitive Landscape

There has been a presence of a considerable number of companies that are significantly contributing to the market growth. New product launches, mergers and acquisitions, partnerships, and collaborations are the key strategies undertaken by these companies for sustainable growth.

Reasons to Purchase this report:

• The market estimate (ME) sheet in Excel format
• Report customization as per the client's requirements
• 3 months of analyst support

Table of Contents

1 INTRODUCTION

• 1.1 Study Deliverables
• 1.2 Study Assumptions
• 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Increasing Government and Private Funding for Glycomics and Proteomics Research
  • 4.2.2 Growing R&D Expenditure by Pharmaceutical and

Biotechnology Companies

• 4.3 Market Restraints
  • 4.3.1 High Product Cost
  • 4.3.2 Low Availability of Skilled Professionals
• 4.4 Porter's Five Force Analysis
  • 4.4.1 Threat of New Entrants
  • 4.4.2 Bargaining Power of Buyers/Consumers
  • 4.4.3 Bargaining Power of Suppliers
  • 4.4.4 Threat of Substitute Products
  • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

• 5.1 By Product
  • 5.1.1 Enzymes
  • 5.1.2 Instruments
  • 5.1.3 Kits
  • 5.1.4 Reagents
• 5.2 By Application
  • 5.2.1 Diagnostics
  • 5.2.2 Drug Discovery and Development
  • 5.2.3 Oncology
  • 5.2.4 Immunology
  • 5.2.5 Other Applications
• 5.3 By End User
  • 5.3.1 Pharmaceutical and Biotechnology Companies
  • 5.3.2 Contract Research Organizations
  • 5.3.3 Other End Users
• 5.4 Geography
  • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
  • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
  • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
  • 5.4.4 Middle-East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
  • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

• 6.1 Company Profiles
  • 6.1.1 Agilent Technologies
  • 6.1.2 Bruker Corporation
  • 6.1.3 Danaher Corporation
  • 6.1.4 Merck KGaA
  • 6.1.5 New England Biolabs
  • 6.1.6 ProZyme
  • 6.1.7 Shimadzu Corporation
  • 6.1.8 Takara Bio
  • 6.1.9 Thermo Fisher Scientific
  • 6.1.10 Waters Corporation

7 MARKET OPPORTUNITIES AND FUTURE TRENDS